Management of treatment resistant schizophrenia in medium secure care

نویسنده

  • Antonio T Lopes
چکیده

nia (TRS) is relatively common, in that between a fifth and a third of service users show a disappointing response to adequate trials of conventional antipsychotic drugs.1–3 The economic burden of this is considerable, both in direct health care costs and loss of productivity due to patients being unable to work. The Schizophrenia Commission report identified the employment rate of patients with schizophrenia as being around 8% in the UK, within a range of 5–15%, against a national UK employment rate of 71%.4 A prospective longitudinal study of TRS patients identified 47 of 59 (79.7%) patients were unemployed at baseline. However, over a 12-month period of clozapine therapy, 23 (48.9%) additional patients were able to gain paid or volunteer jobs, or attend school.5 The average total direct health care costs of treating each patient with schizophrenia amounts to £1670 per year.6 For all patients in the UK, this represents £310 million annually, of which hospital and residential care account for 74% of the total.7 It was initially thought that the target length of stay in medium security hospitals should range between 18 months and two years.8,9 However, several studies have identified that a significant proportion of the medium secure population have treatment needs that extend beyond the twoyear duration.10 Prolonged stay of these patients, many of whom have been transferred from high security psychiatric hospitals, has led to silting up of medium secure beds with inherent consequences for patient flow through the care pathway.11 An earlier study found that, among 21% (25 out of 122) of medium secure male patients who had been admitted for five years or longer, there were high levels of comorbidity and treatment resistance.12 The primary aim of our study was to determine the prevalence of TRS within the male medium secure unit (MMSU). Secondary aims were to establish what factors contributed to long stay, and to use these data towards future service redesign.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

A Randomized Clinical Trial of Group Cognitive-Rehabilitation Therapy for Patients with Schizophrenia Resistant to Medication

Objectives: Against the background of evidence-based treatments for schizophrenia resistant to medication, the implementation of cognitive-Rehabilitation therapy (CRT) becomes more important, especially about patients who don’t response to medication. There is less evidence for group format and face to face structure of CRT and also for resistant to medication patients. This research investigat...

متن کامل

Treatment-Resistant Schizophrenia: Prevalence and Risk Factors

Despite significant progress in the treatment of schizophrenia in recent decades, the evolution of a large rate of patients suffering from this mental disorder is little influenced by treatment [1]. The management of these patients, so-called treatment resistant, constitutes a public health problem. Indeed, these very symptomatic patients often require long periods of hospitalization [2], and t...

متن کامل

Initiating clozapine for treatment-resistant schizophrenia

Substantial changes in cigarette or caffeine consumption may necessitate a dose adjustment of clozapine In 2014, bpacnz published an article on the safer prescribing of clozapine. Since this time, a number of fatalities, along with new research, has reiterated the need for close monitoring of patients treated with this high-risk medicine. Clozapine is often effective for patients with treatment...

متن کامل

Initiating clozapine for treatment-resistant schizophrenia

Substantial changes in cigarette or caffeine consumption may necessitate a dose adjustment of clozapine In 2014, bpacnz published an article on the safer prescribing of clozapine. Since this time, a number of fatalities, along with new research, has reiterated the need for close monitoring of patients treated with this high-risk medicine. Clozapine is often effective for patients with treatment...

متن کامل

Efficacy of Risperidone Augmentation with Ondansetron in the Treatment of Negative and Depressive Symptoms in Schizophrenia: A Randomized Clinical Trial

Background: Given the potential role of the 5-hydroxytryptamine-3 receptor in the pathogenesis of schizophrenia, this study was performed to determine whether ondansetron plus risperidone could reduce the negative and depressive symptoms in patients with treatment-resistant schizophrenia.Methods: In a double-blinded, placebo-controlled, randomized trial (IRCT registration # 201112125280N7), in ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2014